Julian Klein holds a B.Sc. degree in Biotechnology (Germany) and a M.Sc. in Molecular Medicine (Erasmus University, Netherlands). Studying aging-biology, he completed his graduate program at Stanford University.

​

The Glenn Foundation for Medical Research continues to fund his studies on age-related diseases, in particular on antisense oligonucleotides targeting muscle stem cells for the treatment of sarcopenia. Previously, he had been involved in the development of a cell permeable peptide for the treatment of cellular senescence in the context of chronic kidney disease and chemotherapy.

 

His results were published in the prestigious Journal Cell ( Baar et at, 2017 ). The study has drawn worldwide public attention, and ignited a venture-backed company aiming to bring this peptide to the clinic.

 

Moreover, Mr. Klein identified genomic variants that, today, help clinicians to prognosticate the course of sepsis.

 

He also received training in business administration trough Harvard Business School.

​